Zynerba: Falls as cannabis-based drug for rare genetic disorder fails trial

Zynerba Pharmaceuticals

30/06/2020 12:26

** Zynerba Pharmaceuticals Inc's shares  ZYNE.O  fall 46.33%
to $3.51 premarket
    ** Co says its experimental cannabinoid gel, Zygel, failed
to meet main and key secondary goals in a trial in patients with
neurological disorder Fragile X syndrome  urn:newsml:reuters.com:*:nGNXPYpfw
    ** The syndrome is a rare genetic developmental disability
and the leading known cause of both inherited intellectual
disability and autism spectrum disorder
    ** Co says it intends to discuss the study results with the
U.S. FDA
    ** Up to last close, ZYNE stock up ~8% 


 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))